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HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MAJOR THALAS-
SEMIA: NINETEEN YEARS EXPERIENCE IN IRAN
Ghavamzadeh, A., Alimoghaddam, K., Jahani, M., Hamidieh, A.A.,
Mousavi, S.A., Khatami, F., Jalali, A., Alimohammadi, A. Tehran Uni-
versity of Medical Sciences, Tehran, Islamic Republic of Iran
Objective:Hematopoietic Stem Cell Transplantation (HSCT) still
remains the only cure available for Major Thalassemia. Below there
are the results of 19 years using HSCT as treatment in our centre.
Patients and Methods: 425 Major Thalassemia Patients, (242 male
and 183 female) with a median age of 7 (Range: 2-28 years), have re-
ceived HSCT from July 1991 through October, 2009. From 425 pa-
tients, 113 patients were in class I, 146 in class II, 142 in class III and
24 inThalassemia Intermediate. They received allogeneic transplanta-
tion from 407 HLA full matched siblings, nine HLA mismatched sib-
lings or other relatives, nine HLA full matched other relatives. The
sources of HSCT were 158 bone marrow, 194 peripheral blood, 9
cord blood and one bone marrow combined with peripheral blood.
Since three years ago 58 patients with class III thalassemia were ran-
domized for double blind study with two groups; one with co-trans-
plantation (mesenchymalcells) andanotherwithoutmesenchymalcells.
Results:Themedian time toAbsoluteNeutrophilCount$0.5 109/
L and platelet count $20 109/L were +15 and +22, respectively.
Acute GvHD occurred in 281 (66%) and chronic GvHD in 91
(21.4%) patients. 356 (83.8%) patients are still living and 69 (16.2%)
are deceased. The most common cause of death was GvHD. 5-year
overall survival (OS) and disease-free survival (DFS) were 79.8% and
70.2%, respectively. The 5-year OS of patients with peripheral blood
and bone marrow stem cell were 75.5% and 84.2%, respectively
(p5 .141). The 5-year DFS of peripheral blood and bone marrow
recipients were 69.3% and 73.1%, respectively (p5 .773). Up to now
the results ofHSCT for both groups in double blind randomized study
is same and we have to wait for future analysis.
Conclusion: HSCT, based on our experience and other docu-
mented studies, is an acceptable treatment for Major Thalassemia
with better results in younger patients.
KEY WORDS Hematopoietic Stem Cell Transplantation, Major
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IL-15 ENHANCES IN-VITRO EXPANSION AND FUNCTIONAL ACTIVITY OF
ANTIGEN-SPECIFIC EFFECTOR MEMORY T CELLS (TEM) WHILE CO-
EXPRESSION OF IL-15 AND IL-15 R ON ANTIGEN PRESENTING CELLS
ALSO PROMOTES ENRICHMENT AND PREFERENTIAL EXPANSION OF
CENTRAL MEMORY T-CELLS (TCM)
Hasan, A.N.1, Selvakumar, A.1,2, Liu, X.-R.2, Sadelain, M.W.3,
Riviere, I.3, Dupont, B.2, O’Reilly, R.J.1,2 1 Memorial Sloan-Kettering
Cancer Center, New York, NY; 2 Sloan-Kettering Institute, New York,
NY; 3 Memorial Sloan-Kettering Cancer Center, New York, NY
Adoptive immunotherapy with in-vitro expanded antigen-specific
T cells (TC) is often hampered by extended culture times and limited
persistence of infused cells in-vivo. IL-2 predominantly supports the
generation of short-lived effector memory (TEM) and effector (TE)
CD8+ TCwithout expanding the CD62L+ andCCR7+ central mem-
ory TC (TCM), which may persist longer in- vivo. We examined if
IL-15 could foster the growth of CMVpp65-specific TEM and
TCM CD8
+ TC.
TC from 6 HLA-A0201+ seropositive donors were sensitized in-
vitro using HLA-A0201+, CMVpp65+ artificial antigen presenting
cells (Hasan et al. JI, 2009) (A2-AAPC). To assess if trans-presenta-
tion of IL-15 on AAPCs leads to enhanced IL-15 activity, we sequen-
tially transduced A2-AAPCs with the IL-15 and IL-15 Ra cDNA
(A2-AAPCIL-15/IL-15Ra). TC were cultured using A2-AAPC with (i)
IL-2 (20U/ml) (ii) IL-15 (10ng/ml) (iii) IL-2 plus IL-15 or (iv)
A2-AAPCIL-15Ra + IL-2 (20U/ml) (v) A2-AAPCIL-15Ra + IL-15
(10ng/ml) or (vi) A2-AAPCIL-15/IL-15Ra
Starting from a precursor frequency of 0.5-2 x 104/5 million TC,
cultures supplemented with IL-15 demonstrated upto 2000 foldexpansion of CMVpp65 tetramer (+)TC and generated 25-70 x106
A2-NLV tetramer (+) CD8+ TC, compared to a 300-600 fold expan-
sion and 6-12 x106 tetramer (+) CD8+ TCwith IL-2 after 21-28 days.
Sensitization with A2-AAPCIL-15/IL-15Ra exhibited rapid and signif-
icant enrichment of CMVpp65 A2-NLV tetramer (+) CD8+ TC
between day 14-28. There were no TCM detected by 21 days among
tetramer (+) TC in cultures (i) to (v). However, TC sensitized with
A2-AAPCIL-15/IL-15Ra contained 12-15% (7106) tetramer (+)
CD8+ TCM which further increased through day 35. In functional
assays, sensitization with A2-AAPCIL-15/IL-15Ra generated 35-53%
CD8+ CMVpp65 epitope-specific IFNg+ TC compared to 11-26%
in cultures with exogenous IL-15 and 2-10% in cultures with IL-2.
Cytotoxic activity was also higher for TC sensitized with A2-AAP-
CIL-15/IL-15Ra (80-90%) compared to cultures with IL-2 (60%).
These data demonstrate that any condition using IL-15 generates
higher yields of antigen-specific TC. However, TC cultures supple-
mented with IL-15 +/- IL-2 only supported sustained expansion of
TEM and TE. In contrast, TC sensitized with A2-AAPC
IL-15/IL-15Ra
also supported sustained expansion of TCM with augmented
functional activity. Therefore AAPCIL-15/IL-15Ra presents a novel
practical approach for expansion of antigen-specific TCM for adop-
tive immunotherapy.
Differential Expansion and Function of CMVpp65-specific
Memory T-cells
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IN VITRO INDUCTION OF ADENOVIRUS SPECIFIC T-CELLS IN RESPONSE
TO 15-MER PEPTIDES IN UMBILICAL CORD BLOOD
Haveman, L.M.1,2, Bulatovic, M.1,2, Meerding, J.M.2, Prakken, B.1,2,
Bierings, M.1 1 University Medical Center Utrecht, Wilhelmina Child-
ren’s Hospital, Utrecht, Netherlands; 2 University Medical Center Utrecht,
Wilhelmina Children’s Hospital, Utrecht, Netherlands
Human adenovirus (HAdV) infections are a serious life-threat in
hematopoietic stem cell transplantation patients, particularly in chil-
dren. In recent years, umbilical cord blood (UCB) transplants
emerged as an alternative stem cell source. However, the immune
reconstitution is severely hampered in CBT recipients leading to
higher risk of viral infections. Because no effective antiviral medica-
tion exist for severe HAdV infection, replenishing HAdV-specific
immunity through adoptive transfer of HAdV-specific T-cells could
be a promising treatment.
Aim of this study was to induce HAdV-specific T-cells with low
contamination of residual potentially alloreactive T-cells from
UCB. Therefore, cord blood mononuclear cells (CBMCs) were cul-
tured with 5 previously described pan-DR binding 15-mer HAdV
peptides derived from HAdV serotype 5.1 To examine if the mainly
antigen naive UCB T-cells were able to recognize the different
HAdV-peptides, CBMCs of 34 deliveries were cultured with the
HAdV peptides for 5 days without adding supplemental cytokines.
CBMCs of 17 cord blood samples (5 50%) showed a proliferative
response to 43 of the various HAdV-peptides or to the pool of the
peptides, with a stimulation index ranging from 1.7 to 19.1 as deter-
mined by 3H-thymidine proliferation assay. To induce HAdV spe-
cific T-cells, CBMCs derived from 19 deliveries were subsequently
cultured for 7 dayswith theHAdVpeptides or a pool of these peptides
after adding of 40 IU/ml IL2. Compared with medium stimulated
cells HAdV-specific T-cells expressed significantly (p\0.05) more
of the activation markers CD25 and CD69 and harbor a memory
S160 Oral Presentationsphenotype as determined by FACS staining. The cells produced the
pro-inflammatory cytokines IL1b, IL6, IL17, IP10, IFNg and
TNFa as determined byMultiplex immuno-assay and the cytotoxins
perforin and granzyme B, all necessary for viral elimination.
The generation of HAdV specific T-cells from naive UCB cells in
response to 15-mer HAdV peptides seems an essential step in devel-
oping a more tailor-made adoptive therapy for HAdV infection for
recipients of UCB transplants.
1 Haveman,LM,BieringsM,LeggerE, et al.Novel pan-DR-bind-
ingT-cell epitopes of adenovirus induce pro-inflammatory cytokines
and chemokines in healthy donors. Int Immunol. 2006;18:1521-9.15
FLAGELLIN-TLR5 IMMUNE RESPONSE: A NOVEL MECHANISM TO RE-
DUCE GVHD IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION
Hossain, M.S.1, Gewirtz, A.T.2, Roback, J.D.2, Waller, E.K.1 1 Emory
University, Atlanta, GA; 2 Emory University, Atlanta, GA
Background: Immunosuppressive drugs are used to limit GvHD
but causes complications. To develop an alternative approach to
control GvHD, we tested the immunomodulatory immune proper-
ties of flagellin, a bacterial protein that agonistically binds with
TLR5.
Methods:We used established B6 to CB6F1 and B10.BR to B6 allo-
geneicHSCT recipients had both acute and chronicGvHD. 50 mg fla-
gellin administered i.p 3 hours before 11 Gy irradiation. 5 million (M)
T-cell depleted bone marrow (TCDBM) and 5 M splenocytes of con-
geneic donors were transplanted i.v. 24 hours later another dose of fla-
gellin were administered i.p. Control recipients were treated with
0.2 ml PBS i.p. HSCT mice were monitored every day for mortality.
Weight of individual mice was measured twice a week until 30 days
post transplant and once a week after that tomeasureGvHD. Immune
reconstitution was determined by measuring immune cells/organs and
infecting the recipients with 510E3 pfu MCMV i.p.
Results: Flagellin treated recipients of in B6 to F1 model survived
100% and gained weight to almost normal level within 66 days post
transplant.But the control groupsurvived80%andhadsignsof chronic
GvHD. Flagellin-treated recipients in B10 to B6 model had 15%
weight-loss and 33% transplant-related death by 132 days post trans-
plant versus had severe acute GvHD and 100% early post-transplant
mortality amongcontrolHSCTrecipients. Flagellin-treated recipients
in B6 to F1 model showed 100% chimerism with significantly higher
number of donor spleen- and BM-derived CD4+ and CD8 +T cells
per spleen inuntreated recipientscompared tocontrol recipientswithin
66 days post transplant. In the spleen CFSE labeled CD4 +T cells di-
vided faster in flagellin-treated recipients than the control recipients
and decreasing the number of CD4 +CD62L+ T cells within 4 days
post transplant. B6 to F1 recipients were infected with MCMV on
70+dayspost transplant.Controlmicediedwithinday10post infection
whereas flagellin-treated recipients recovered from MCMV infection
and had higher number anti-viral+ CD8 +T cells in their blood on
day 10 and 35 post infection. Increased numbers of
CD25+foxp3 +CD4+ regulatoryT cells were alsomeasured from their
thymus on day 35 post MCMV infection.
Conclusion: Flagellin treatment successfully controlled GvHD, en-
hances donor T-cell engraftment, had brisk and persistent cellular
immune responses in lymphoid organs to protect recipients from vi-
ral infection.16
FACTORS PREDICTING NEW-ONSET DIABETES MELLITUS AND META-
BOLIC SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION:
IMPLICATION FOR EARLY PREVENTIVE INTERVENTION
Griffith, M.L.1, Misfeldt, A.A.1, Chen, H.2, Jagasia, M.3, Kassim, A.3,
Savani, B.N.3, Survant, M.1, Jagasia, S.M.1 1 Vanderbilt University
Medical Center, Nashville, TN; 2 Vanderbilt University Medical Center,
Nashville, TN; 3 Vanderbilt University Medical Center, Nashville, TN
Background: Incidence and risk factors for post-transplant diabetes
mellitus (PTDM) and long-term development of metabolic syn-drome (MS) after allogeneic stem cell transplantation (allo-SCT)
are not well defined.We conducted a prospective study of 84 patients
(pts) undergoing allo-SCT with cyclosporine-based graft-versus-
host disease (GVHD) prophylaxis to evaluate risk factors and inci-
dence of PTDM in the first 100 days. Prevalence of MS at long-
term followup was assessed.
Methods: Allo-SCT candidates without preexisting DM who met
screening criteria were enrolled. Demographic data and baseline
laboratory data including fasting blood glucose (FBG), lipids, insu-
lin, c-peptide, and fructosamine were collected. PTDM was de-
fined by FBG. 126 mg/dl or random BG. 200. Peak dose and
duration of systemic steroid (SS) treatment for GVHD was col-
lected. MS was defined by NCEP ATPIII criteria based on annual
screens.
Results:Median age of pts was 46 years (yrs) (range 21-66). 44 (52%)
were male. Median FBG pre-SCT was 97 (range 79-121). 50 of 84
(60%) pts developed DM at median of 23 days (interquartile range
14.2-33.8) post-transplant. 33 pts completed study to day 100 with-
out PTDM and 1 died before day 100 without PTDM. Age was sim-
ilar regardless of PTDM development. 28 pts (56%) with PTDM
and 16 pts (47%) without PTDMwere exposed to SS prior to reach-
ing endpoints of PTDM or day 100. Pre-transplant c-peptide levels
were higher in pts with PTDM (median 4.45 mg/dL vs 2.55,
p5 0.015). Among pts receiving SS before day 100, pts with
PTDM were more likely to have received. 1 mg/kg/day of SS
(p5 0.002). Median post-transplant followup was 1.5 yrs (range 18
days-3.6 yrs). 45 pts (54%) were screened for MS at their annual
or subsequent visits (17 pts deceased prior to 1 yr post-SCT). Of
the pts for whom long-term metabolic data were collected, 17
(38%) met criteria for MS. Compared to pts who did not develop
MS, these pts were older (56 vs 41.5 yrs, p5 0.005) and had higher
pre-transplant fasting triglyceride levels (177 vs 108 mg/dl,
p5 0.005). Interestingly, GVHD and use of SS were not associated
with development of MS.
Conclusions: Our data suggest that pre-SCT c-peptide predicts
PTDM, while high triglyceride levels and older age associate with
long-termMS.These findingsmay helpwith counseling,monitoring,
and planning interventions to reduce metabolic sequelae after allo-
SCT, which contribute to cardiac complications in young patients af-
ter allo-SCT.17
AUGMENTATION OF HEMATOPOIETIC ENGRAFTMENT WITHOUT GRAFT
VERSUS HOST DISEASE BY ‘‘ADD-BACK’’ OF PHOTOCHEMICALLY
TREATED T LYMPHOCYTES IN MISMATCHED CORD BLOOD TRANSPLAN-
TATION
Kanathezhath, B.1,2, Neumayr, L.1, Guo, H.1, Walters, M.C.1,
Kuypers, F.A.2 1 Children’s Hospital & Research Center, Oakland, CA;
2 Children’s Hospital Oakland Research Institute, Oakland, CA
Introduction: Unrelated cord blood transplantation (CBT) is asso-
ciated with a risk of graft rejection due in part to a limiting cellular
content of the CB unit.We have investigated the co-infusion of pho-
tochemically (psoralen S59) treated mature donor T lymphocytes in
a major histocompatibility complex (MHC) [H2-haplotype] mis-
matched murine transplant model as a new method to facilitate en-
graftment of donor CB cells.
Methods: We analyzed the rates of donor hematopoietic cell en-
graftment, graft versus host disease (GVHD), and long-term survival
in H2 haplotype disparate [C57BL/6 (H2Kk/Thy1.1)/AKR
(H2Kb/Thy1.2)] mice after CBT. Three different experimental
groups were transplanted after sublethal radiation. Group 1 received
allogeneic full term newborn peripheral blood alone, group 2 was
transplanted with the same donor cells and unmanipulated donor
T cells, and group 3 was transplanted with the similar donor cells
and psoralen (S-59) treated donor T cells.
Results:We observed a low rate of donor engraftment after trans-
plantation with cord blood alone (Group 1). The best results were
observed after transplantation with 3 x 106 nucleated cord blood
cells and 9 x106 S-59 treated T cells (Group 3b)(p5 0.007).
The engraftment rate was 75% compared to 12.5% after trans-
plantation with 6 x 106 CB cells alone (p5 0.04). The long-
term survival in group 3 was 100% and the rate and severity of
